Prognostic Role of Primary Tumor Location in Non-Metastatic Gastric Cancer: A Systematic Review and Meta-Analysis of 50 Studies
- 447 Downloads
The incidence of gastric cancer (GC) arising in the upper third of the stomach, including the cardia or gastroesophageal junction (GEJ), has increased in the last decades due to established etiological risk factors such as diet, obesity, and gastroesophageal reflux. We conducted a systematic review and meta-analysis to determine the prognostic role of site of origin in patients with proximal versus distal GC.
Material and Methods
We conducted a search of the PubMed, Cochrane Library, SCOPUS, Web of Science, EMBASE, Google Scholar, LILACS, and CINAHL databases from inception to September 2016. Studies reporting data on the independent prognostic effect of site in GC and comparing overall survival (OS) in proximal versus distal tumors were eligible. Data were pooled using OS hazard ratios (HRs) of proximal versus distal GC according to fixed- or random-effect model.
Overall, 50 studies including 128,268 patients were identified. Cancers located in the upper third of the stomach were associated with a significantly increased risk of all-cause mortality (HR 1.31, 95% confidence interval [CI] 1.17–1.46, p < 0.001, I 2 = 91%). After exclusion of GEJ tumors, prognosis was worse for pure cardia location (HR 1.39, 95% CI 1.22–1.58, p < 0.001, I 2 = 61%) compared with proximal or upper-third GCs without a specific subsite definition (HR 1.18, 95% CI 1.01–1.37, p = 0.04, I 2 = 91%).
Location of the primary GC in the upper third of the stomach, particularly at the GEJ/cardia, should be acknowledged as an important prognostic factor. Based on these results, more effective treatment strategies for proximal GCs are needed.
KeywordsGastric Cancer Overall Survival Human Epidermal Growth Factor Receptor Proximal Tumor Gastric Cardia
Fausto Petrelli, Michele Ghidini, Sandro Barni, Francesca Steccanella, Giovanni Sgroi, Rodolfo Passalacqua, and Gianluca Tomasello declare no conflict of interest.
- 9.Van Laethem JL, Carneiro F, Ducreux M, et al. The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona. Dig Liver Dis. 2016;48(11):1283–89.CrossRefPubMedGoogle Scholar
- 11.Wells G, Shea B, O’Connell D. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. 2015. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 29 Dec 2015.
- 37.Liu K, Zhang W, Chen X, et al. Comparison on clinicopathological features and prognosis between esophagogastric junctional adenocarcinoma (Siewert II/III types) and distal gastric adenocarcinoma: retrospective cohort study, a single institution, high volume experience in china. Medicine. 2015;94(34):e1386.CrossRefPubMedPubMedCentralGoogle Scholar
- 38.Marchet A, Mocellin S, Ambrosi A, et al. The ratio between metastatic and examined lymph nodes (N ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy: results from an Italian multicentric study in 1853 patients. Ann Surg. 2007;245(4):543–52.CrossRefPubMedPubMedCentralGoogle Scholar
- 44.Pedrazzani C, Sivins A, Ancans G, et al. Ratio between metastatic and examined lymph nodes (N ratio) may have low clinical utility in gastric cancer patients treated by limited lymphadenectomy: results from a single-center experience of 526 patients. World J Surg. 2010;34(1):85–91.CrossRefPubMedGoogle Scholar
- 61.Wu H-L, Tian Q, Peng C-W, Liu S-P, Li Y. Multivariate survival and outcome analysis of 154 patients with gastric cancer at single Chinese institution. Asian Pacific J Cancer Prev. 2011;12:3341–45.Google Scholar
- 69.Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1–241.Google Scholar
- 80.Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.CrossRefPubMedGoogle Scholar